Hormonal
GLP-1 receptor agonists (e.g., semaglutide 2.4 mg) produce clinically significant weight loss and reduce major adverse cardiovascular events (MACE) in adults with obesity or overweight, regardless of diabetes status.
GLP-1 medications like semaglutide are highly effective for weight loss and heart health, even if you don't have diabetes. While injections are common, oral versions exist. Be aware that cost and side effects (like nausea) can make sticking with the treatment difficult, so discuss these barriers with your doctor early.
Henry's trials firmly demonstrated weight-loss efficacy with weekly semaglutide 2.4 mg (STEP program)... There was a 20% risk of major adverse cardiovascular events (MACE) in a group of 17,604 overweight or obese people without diabetes who were randomized to the drug semaglutide 2.4 mg (vs. placebo).
Why this rating
The claim is supported by large-scale randomized controlled trials (STEP, SELECT, FLOW) cited in the text.
Source
GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Megha Pawar et al. · BioMed Target Journal · 2025
DOI 10.59786/bmtj.322
More from this paper
- GLP-1 receptor agonists provide renoprotective effects by slowing eGFR decline and reducing albuminuria in patients with type 2 diabetes and chronic kidney disease.Strong
- Dual and triple incretin agonists (e.g., tirzepatide, retatrutide) offer superior weight loss and glycemic control compared to single GLP-1 agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →